April 16, 2018 — Varian announced a new version of its Velocity cancer imaging software that includes Rapidsphere, a module for Y90 selective internal radiation therapy (SIRT) dosimetry analysis. Rapidsphere provides the ability for cancer care teams to better understand tumor response and normal-tissue toxicity for individual patients receiving SIRT. This new software module extends Varian's Velocity software to interventional radiologists for use in targeted cancer therapy delivery to patients with liver malignancies.
Velocity 4.0 and the Rapidsphere module have received U.S. Food and Drug Administration (FDA) 510(k) clearance.
Rapidsphere runs on the Velocity software platform, which aggregates unstructured treatment and imaging data from diverse systems to show a comprehensive view of a patient's diagnostic imaging and treatment history. Rapidsphere is an integrated image-guided dosimetry system for calculating the absorbed dose using post-treatment emission tomography imaging from Y90 SIRT.
Velocity 4.0 incorporates several new features or improved functionalities. Additional new features in the software include:
- Velocity M3i (Multi-Modality Motion Imaging) — Simultaneous display and contouring of up to 10 imaging studies; (CT/MR/PET/SPECT/Ultrasound/4DCT/CBCT) with deformable image registration;
- Velocity Aria Sync — Automatic synchronization of approved objects from Aria and Eclipse and one-click save of Velocity data with Aria and Eclipse; and
- Velocity Tumor & Dose Tracking – Image-based tumor and radiotherapy dose tracking across multiple treatment courses and therapy modalities to verify both volumetric tumor change and the cumulative dose history for cancer patients
For more information: www.varian.com
April 18, 2024 
